Although the sample size is limited, these clinical sample results further corroborate our findings on STAT3-mediated SUSD2 upregulation in EGFR+ HER2+ breast cancer, underscoring the clinical significance of SUSD2 expression. Here, ERBB2 is linked to breast carcinoma.